Navigation Links
MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
Date:11/5/2007

VALENCIA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced results from a Phase 1a clinical evaluation of MKC253, a formulation of GLP-1 (glucagon-like peptide) on Technosphere particles that is delivered using the Company's proprietary inhaler. The study was designed as an open-label, dose escalation, controlled safety and tolerability trial, involving 26 healthy, adult, male subjects. Each subject was assigned to one of five dose levels of MKC253 inhalation powder: 0.05 mg, 0.45 mg, 0.75 mg, 1.05 mg or 1.5 mg.

The primary objective of the trial was to evaluate the tolerability of ascending doses of the investigational product as determined by the incidence and severity of reported adverse events. Secondary endpoints included pharmacokinetic parameters of plasma GLP-1 and pharmacodynamic parameters of plasma insulin and glucose.

GLP-1 plasma concentrations peaked very quickly, with a mean Tmax occurring less than 3 minutes after inhalation. In the group that received 1.5 mg of MKC253, the mean Cmax of total GLP-1 was 507 pmol/L, with active GLP-1 reaching a Cmax of 310 pmol/L. At all dose levels, MKC253 was well tolerated. Even in subjects that achieved plasma GLP-1 concentrations in excess of 100 pmol/L, the nausea and vomiting characteristically associated with such levels was not observed.

In these healthy subjects, GLP-1-induced insulin release occurred within 6 minutes of inhalation of MKC253. The insulin response was dose-dependent. The release of insulin from the pancreas was confirmed by corresponding significant increases in the levels of C-peptide. In subjects that received 1.5 mg of MKC253, blood glucose concentrations were observed to decrease
'/>"/>

SOURCE MannKind Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... England , Nov. 21, 2014   TRU-D SmartUVC ... will feature their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, ... this week from Nov. 23 to 26 at Stand 23. ... is the United Kingdom,s largest infection-related ... infection prevention societies to one of the leading events of ...
(Date:11/21/2014)... 20, 2014 The California ... research organization representing leading California academic institutions, biotechnology, ... PwC US today released a report revealing ... industry growth. The trend shows a 4 percent ... California Biomedical Industry Report indicates that, while ...
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") ... a brokered private placement offering (the "Brokered Offering") ... Securities Inc. and Clarus Securities Inc. acted as ... syndicate of agents that also included Wolverton Securities ... Concurrently with the Brokered Offering, the Company also ...
Breaking Biology Technology:TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... SAFC Pharma(TM), a focus,area within SAFC(R), a member ... announced that a new reactor at its Arklow ... capacity for large-scale,active pharmaceutical ingredient (API) manufacturing by ... a series of investments designed to,enhance production capacity ...
... JOSE, Calif., Sept. 26 Dr. Qi Lu, former EVP ... and serve as the president of HYSTA, USA. HYSTA is ... officially left Yahoo! at end of August, he had served ... both personally and professionally,but one thing that has not changed ...
... PIP ), a biodefense company developing medical ... the National,Institute of Allergy and Infectious Diseases (NIAID), ... awarded the Company a multi-year contract,for up to ... generation,recombinant protective antigen (rPA) anthrax vaccine., The ...
Cached Biology Technology:SAFC Pharma Completes Large-Scale API Manufacturing Expansion in Ireland 2SAFC Pharma Completes Large-Scale API Manufacturing Expansion in Ireland 3Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA 2PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 2PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 3PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 4PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 5PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 6
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2
... 12, 2009) German scientist Otto H. Warburg,s theory ... Prize in 1931, but the biochemical basis for his ... from irreversible injury to cellular respiration eventually fell out ... the cause of uncontrolled cell growth. Seventy-eight years ...
... Fla. A Mayo Clinic-led international consortium has ... and other neurological disorders. Studying just ... have discovered a genetic defect that results in ... as Perry syndrome. Although this syndrome is exceedingly ...
... 12 Industry Leaders Chosen for BOSS-UROCKVILLE, Md., Jan. 8 ... named Lockheed Martin (NYSE: LMT ) an industry ... Operations and Support Services - Unrestricted (BOSS-U) vehicle. As ... selected to participate in this indefinite delivery, indefinite quantity (ID/IQ) ...
Cached Biology News:Nearly a century later, new findings support Warburg theory of cancer 2Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases 2Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases 3Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases 4Lockheed Martin Team Wins Role on Key Department of Defense Biometrics Contract Vehicle 2
... weight determinations for petroleum-based applications. Multiple solvents can be used, such as water, benzene, formamide, ... ... ... ...
Fast, sensitive quantitation of total MEK 1/2 concentration....
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
... Automatic High Sensitivity Laboratory Osmometer for 50 L samples. Operating head automatically rises at the end of ... ... ... ...
Biology Products: